Pharmaceutical

Be Bio secures $92m for haemophilia B and hypophosphatasia treatments

Be Biopharma has secured $92m in a Series C financing round to advance its clinical programmes for haemophilia B and hypophosphatasia.

Jan 16, 2025 - 06:00
Be Bio secures $92m for haemophilia B and hypophosphatasia treatments
Be Biopharma has secured $92m in a Series C financing round to advance its clinical programmes for haemophilia B and hypophosphatasia.
Read the original article

Tags:

Previous Article

Revolutionary Tiny Anticancer Weapon Developed by Penn Medicine Scientists

Next Article

Lilly gains US FDA approval for Omvoh to treat Crohn’s disease

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Q&A: What does it mean when a clinical trial is delayed? More than you think

Q&A: What does it mean when a clinical trial is delayed...

Apr 17, 2023

Surufatinib by Hutchison MediPharma for Neuroendocrine ...

Oct 25, 2023

Do GLP-1s have a future treating alcoholism?

Do GLP-1s have a future treating alcoholism?

Dec 1, 2023